Detection of Bet v 1-specific IgG-producing cells in birch pollen-allergic patients and healthy controls by ELISPOT analysis

被引：0
|
作者：
Baum, C. [1 ]
Moebs, C. [1 ]
Pfuetzner, W. [1 ]
机构：
[1] Univ Marburg, Clin & Expt Allergol, Dept Dermatol & Allergol, D-35043 Marburg, Germany
来源：
EXPERIMENTAL DERMATOLOGY | 2016年 / 25卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P011
引用
收藏
页码：E2 / E2
页数：1
相关论文
共 50 条
  • [41] Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome
    Gehlhar, K
    Schlaak, M
    Becker, WM
    Bufe, A
    CLINICAL AND EXPERIMENTAL ALLERGY, 1999, 29 (04): : 497 - 506
  • [42] Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1
    Daniel, C.
    Repa, A.
    Wild, C.
    Pollak, A.
    Pot, B.
    Breiteneder, H.
    Wiedermann, U.
    Mercenier, A.
    ALLERGY, 2006, 61 (07) : 812 - 819
  • [43] ANTI-BET V_1 MABS REDUCED BASOPHIL RESPONSIVENESS TO BIRCH POLLEN STIMULATION EX-VIVO IN BIRCH ALLERGIC PATIENTS
    DeCraemer, J.
    Gevaert, P.
    DeRuyck, N.
    Herrera, O.
    Deveaux, M.
    Ramesh, D.
    Perlee, L.
    O'Brien, M.
    Wang, C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S19 - S19
  • [44] Clinical efficacy of subcutaneous immunotherapy in birch pollen allergic patients: a randomized, double-blind, placebo-controlled study with recombinant Bet v 1 versus natural Bet v 1 or standardized birch extract
    Pauli, G.
    Malling, H. -J.
    Rak, S.
    Horak, F.
    Pastorello, E. A.
    Purohit, A.
    Larsen, T. H.
    Arvidsson, M.
    Kavina, A.
    Szaal, S.
    Schroeder, J.
    Vighi, G.
    Galvain, S.
    Andre, C.
    Melac, M.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2006, 36 (09): : 1206 - 1206
  • [45] Peptide mimotopes displayed by phage inhibit antibody binding to Bet v 1, the major birch pollen allergen, and induce specific IgG response in mice
    Jensen-Jarolim, E
    Leitner, A
    Kalchhauser, H
    Zürcher, A
    Ganglberger, E
    Bohle, B
    Scheiner, O
    Boltz-Nitulescu, G
    Breiteneder, H
    FASEB JOURNAL, 1998, 12 (15): : 1635 - 1642
  • [46] Different profiles in specific IgE to rBet v 1 and rBet v 2 in patients allergic to birch pollen from six countries
    Elfman, L
    Svensson, M
    Lidholm, J
    Pauli, G
    Valenta, R
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1997, 113 (1-3) : 249 - 251
  • [47] Human monoclonal IgG antibodies derived from a birch pollen allergic patient as tools to study the in situ localization of Bet v 1 allergen by immunogold electron microscopy
    Grote, M
    Wiedemann, P
    Lebeque, S
    Valenta, R
    EUROPEAN JOURNAL OF CELL BIOLOGY, 1997, 74 : 42 - 42
  • [48] Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1.: Anti-allergen IgG can enhance the anaphylactic reaction
    Denépoux, S
    Eibensteiner, PB
    Steinberger, P
    Vrtala, S
    Visco, V
    Weyer, A
    Kraft, D
    Banchereau, J
    Valenta, R
    Lebecque, S
    FEBS LETTERS, 2000, 465 (01) : 39 - 46
  • [49] Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy
    Linhart, B.
    Narayanan, M.
    Focke-Tejkl, M.
    Wrba, F.
    Vrtala, S.
    Valenta, R.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2014, 44 (02): : 278 - 287
  • [50] IgE and allergen-specific immunotherapy-induced IgG4 recognize similar epitopes of Bet v 1, the major allergen of birch pollen
    Groh, N.
    von Loetzen, C. S.
    Subbarayal, B.
    Moebs, C.
    Vogel, L.
    Hoffmann, A.
    Foetisch, K.
    Koutsouridou, A.
    Randow, S.
    Voelker, E.
    von Loetzen, A. Seutter
    Roesch, P.
    Vieths, S.
    Pfuetzner, W.
    Bohle, B.
    Schiller, D.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2017, 47 (05): : 693 - 703
12345